Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 14Observational 1

Sponsor

Cancer Type

Gastrointestinal 26Thoracic 20Tumor-Agnostic 3Breast 2Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Immune Checkpoint Inhibitors × Genitourinary × Clear all
NCT05037825 2022-04-27

PARADIGM

VastBiome

Recruiting
800 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡